GALDERMA
Galderma, the emerging pure-play dermatology category leader, announced today it has received approval from Health Canada for Restylane® SHAYPE™, a hyaluronic acid (HA) injectable designed for temporary augmentation of the chin region.2 Engineered to build and shape on bone with deep injection for a bone-mimicking effect,1,2,3,4† Restylane® SHAYPE™ will be available in Canada as of February 2024.
The chin is a critical component of overall appearance that influences the balance of facial proportions, profile, and shape.5,6,7,8 Genetics and age can impact overall chin definition,6,9 which may cause the appearance of a double chin, or “weak chin.” For decades, there has been heavy reliance on implants to create structure in the lower face, with no non-surgical options available offering qualities close to an implant.
Powered by new NASHA HD™ technology from Galderma,4 Restylane® SHAYPE™ has the highest G’ (“G prime”) of the Restylane® range.1,11 The firmest HA gel available on the market,1,2* Restylane® SHAYPE™ allows aesthetic injectors to shape, project and elongate the chin2,3 for natural-looking results from any angle.3‡ As a minimally modified and particularly firm HA gel,10 Restylane® SHAYPE™ is the injectable closest to the HA naturally found in skin10 and can be readily reversed.2,12,13
“Restylane® SHAYPE™ is the next generation in HA, going beyond currently available options for chin augmentation. Developed with leading experts, this innovative breakthrough has a unique ability to create the strength and support needed for a bone-mimicking effect. This makes Restylane® SHAYPE™ an ideal choice for lower face shaping, offering durable, natural-looking results for up to 12 months without retreatment.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA
In a pivotal 12-month study conducted at nine sites across Canada, 91% of patients agreed they still had aesthetic improvements at 12 months, and 84% of patients would agree to be treated with Restylane® SHAYPE™ again. Furthermore, up to 97% of patients would recommend treatment with Restylane® SHAYPE™ to a friend and 95% of patients felt their results looked natural.3
“A product with a significant ability to create a bone-mimicking effect without the downtime of surgery has long been an unmet need, highlighted by the community of plastic surgeons, dermatologists, and aesthetic injectors all over the world. The development of the ideal gel required a significant increase in firmness to create the strength and support needed to shape the lower face. Now, through meticulous clinical evaluation, Galderma has achieved the development of a safe and effective HA injectable for chin remodeling.”
DR. ANDREAS NIKOLIS, M.D., Ph.D., FRCSC, BOARD-CERTIFIED PLASTIC SURGEON
PRINCIPAL INVESTIGATOR, RESTYLANE® SHAYPE™ PIVOTAL STUDY
MONTREAL, CANADA
Other regulatory reviews around the world are ongoing, and Galderma is working to bring this latest innovation to as many countries as possible.
About Galderma’s RESTYLANE® portfolio
RESTYLANE® is produced using the NASHA HD™ technology and is the original hyaluronic acid filler, with over 27 years of clinical experience and over 65 million treatments worldwide. NASHA® and OBT™ are complementary technologies that make RESTYLANE® the world’s most diverse range of fillers, for any and every look.
About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References |
1 Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G' including Restylane® SHAYPE™). |
2 Restylane® SHAYPE™ IFU. IFU-0103. August 2023. |
3 Galderma. Data on file. MA-53870. 2023. Restylane® SHAYPE™ 43BBJ2001 Clinical Study Report. |
4 Galderma. Data on file. MA-56848. 2023. Technical data for Restylane® SHAYPE™. |
5 Braz A, Eduardo CCP. Indian J Plast Surg. 2020;53(2):207–18. |
6 Schmid PM. Advances in Cosmetic Surgery. 2019;2(1):11–21. |
7 Gewargis J, Swaminathan V. J Aesthet Nurse; 2021:10(8);1–9. |
8 Galderma. Data on file. 2022. AART Methodology Comprehensive Training Deck. |
9 Sykes JM, Fitzgerald R. Facial Plast Surg. 2016;32(5):507–12. |
10 Galderma. Data on file. MA-58650. 2023. Degree of modification of HA fillers. |
11 Galderma. Data on file. MA-34483. 2023. xStrain and G' (US). |
12 Paap MK, Silkiss RZ. Plast Aesthet Res. 2020;7:36. |
13 Jung H. Arch Plast Surg. 2020;47(4):297–300. |
† The highest G' of the Restylane® range, a deep (supraperiosteal) injection depth and indication for chin augmentation together mean Restylane® SHAYPE™ can achieve a bone-mimicking effect. |
‡ Patients could receive a touch-up at Month 1. |
* Based on the products marketed in Canada as of December 2023. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240121172418/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Coca-Cola Company and Gutsche Family Investments Agree to Sell Controlling Interest in Coca-Cola Beverages Africa to Coca-Cola HBC AG21.10.2025 08:00:00 CEST | Press release
The Coca-Cola Company and Gutsche Family Investments have agreed to sell a 75% controlling interest in Coca-Cola Beverages Africa Pty. Ltd. to Coca-Cola HBC AG, the companies announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020939952/en/ CCBA is the largest Coca-Cola bottler in Africa. It operates in 14 countries on the continent and accounts for about 40% of all Coca-Cola product volume sold across Africa. Coca-Cola HBC is one of the largest Coca-Cola bottlers in the world, with operations in 29 countries across Europe and Africa, including Nigeria and Egypt. Coca-Cola will sell 41.52% out of its 66.52% stake in CCBA to Coca-Cola HBC, and Coca-Cola HBC is acquiring 33.48% of CCBA that is held by GFI. In total, the transaction values 100% of CCBA at an equity value of US$3.4 billion. The transactions are targeted to close by the end of 2026. Coca-Cola and Coca-Cola HBC have also agreed to a separate option
Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation21.10.2025 08:00:00 CEST | Press release
Six early-career scientists and clinicians will receive $150,000 each to conduct research on metabolic therapies for mental health Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The award represents a significant step forward in growing the rapidly advancing field of metabolic psychiatry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020666940/en/ Baszucki Group 2025 Metabolic Psychiatry Scholar Award Recipients The six scholars will each receive up to $150,000 over 18 months for original research in metabolic psychiatry. The award program advances Baszucki Group’s mission to transform mental health outcomes through research at the intersection of metabolism, psychiatry, and neuroscienc
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer21.10.2025 07:17:00 CEST | Press release
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC) No dose-limiting toxicities and no treatment-related serious adverse events observed Xerostomia predominantly Grade 1 80% PSA50 response at doses ≥ 160 MBq 100% objective response rate (ORR) in patients with RECIST-measurable lesions, including two complete responses (CRs) The data represent the first clinical trial results for a Lead-212 (212Pb)-based PSMA-targeted radioligand therapy and highlight the potential of 212Pb-ADVC001 to enhance therapeutic options for patients with prostate cancer Phase 2 expansion will evaluate 160 MBq and 200 MBq of 212Pb-ADVC001 using a randomized multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes in three indications: mCRPC (chemo-naïve, and post-177Lu-PSMA) and hormone-sensitive prostate cancer (mHSPC) AdvanCell, a clin
GigaDevice Deepens Commitment to Japan, Advancing Local Services and Global Collaboration21.10.2025 05:57:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially opened its new office in Minato City, Tokyo. This milestone reflects the company’s deepening commitment to the Japanese market and marks a significant step in enhancing local customer support, strengthening regional collaboration, and advancing its global development efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020247226/en/ GigaDevice executives and employees celebrate the opening of the new Japan office in Minato City, Tokyo. Japan has long served as a vital pillar of GigaDevice’s global strategy. Over the years, the company has expanded its local team, refined operation to meet evolving customer needs, and established a responsive professional service system. This new office will further enhance GigaDevice’s technical responsiveness and agility, foster closer
Streamlining Project Efficiency with Murata’s Pre-Installed Electrical Models in the Latest Versions of Cadence OrCAD X Capture™, Allegro X System Capture™ and AWR Design Environment™ (Microwave Office)21.10.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a significant collaboration with Cadence Design Systems, Inc., making product libraries directly accessible within Cadence’s leading Electronic Design Automation (EDA) tools. Murata’s selected inductor and capacitor products are now pre-installed in the latest versions of Cadence OrCAD X Capture™, Allegro X System Capture™ and AWR Design Environment™ (Microwave Office). By enabling engineers to select Murata components directly within these tools and run simulations, this initiative is set to refine circuit design and streamline the design process for power supply, high-frequency, and noise suppression circuits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020071479/en/ [Murata Manufacturing Co., Ltd.] Collaboration with Cadence Design Systems, Inc. Advancements in IC performance and increased circuit complexity on PCBs are driving the industry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom